Researchers have created a map of human skin that uses genomics and other technologies to understand how skin forms and the mechanisms behind skin disorders.
Roche's Alecensa has been recommended for routine NHS use as an adjuvant treatment for ALK-positive non-small cell lung cancer (NSCLC), the first targeted therapy for this indication.